Andrea Fava
@andreafava
Followers
556
Following
750
Media
24
Statuses
282
Rheumatologist and physician scientist @JohnsHopkins 🇮🇹🇺🇸| Studying mechanisms of #Lupus | Immunology | Computational biology
Baltimore, MD
Joined January 2010
So excited to share our latest with Betty Diamond and many colleagues from the AMP RA/SLE consortium, @NIH_NIAMS , and @NIAIDNews ! A large-scale blood and tissue atlas of Lupus Nephritis!
biorxiv.org
Lupus nephritis (LN), a severe manifestation of Systemic lupus erythematosus (SLE), is a heterogeneous disease driven by diverse immune and tissue cell types. Current treatments of LN are non-speci...
0
6
13
NEW Correspondence—Preload deficiency as a treatable cause of fatigue and exercise intolerance in #SLE
https://t.co/SbRcEhSKUS
0
5
13
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE - The Lancet Rheumatology
thelancet.com
Fatigue and exercise intolerance affect more than 90% of patients with systemic lupus erythematosus (SLE), often persisting despite inactive disease.1 The pathophysiology of the disease remains...
1
1
5
@YooJinKimYJK led our @hopkinsheart + @andreafava @HopkinsRheum team in investigating recurrent pericarditis in Lupus. Oral prednisone therapy increased recurrence risk. Further evidence that prednisone should be minimized in lupus?@JAMANetworkOpen
jamanetwork.com
This cohort study investigates the incidence of recurrent pericarditis among patients with a history of systemic lupus erythematosus (SLE) and factors associated with recurrence.
1
5
17
268/279 SLE pts w/ kidney biopsy for proteinuria were Dx w/ lupus nephritis. Proliferative LN (III/IV+V) had higher levels of C1q, chromatin, dsDNA, ribosomal P Abs. C1q & dsDNA independently assoc w/ proliferative LN. AutoAbs decreased in proliferative LN https://t.co/tRucgJRpDN
0
7
18
Levels of anti-C1q and anti-dsDNA were independently associated with proliferative lupus nephritis In proliferative LN, higher baseline anti-C1q levels predicted complete response better than baseline proteinuria In A&R https://t.co/vaA7fv9lyP
0
20
39
Tomorrow #preprintHub1 @nicolas_ruffin from @karolinskainst will present a #preprint by @luigiadamomdphd lab showing how B cell-mediated antigen presentation promotes adverse cardiac remodelling in chronic heart failure 🫀🩺👷♀️ https://t.co/gO993aiBAb
biorxiv.org
Cardiovascular disease remains the leading cause of death worldwide. A primary driver of cardiovascular mortality is ischemic heart failure, a form of cardiac dysfunction that develops in patients...
2
13
18
Low urinary IL16 levels at 12 months predicts kidney survival at 3 years better than proteinuria - @Andreafava @rheumnow #RNL2024
0
3
13
Thanks to @FNIH_Org, @NIDDKgov , @NIH_NIAMS, @LupusOrg, @LupusResearch, the Jerome L Greene Foundation, and the Plank Foundation for their support to this work and its future development!
0
0
3
🔬 Exciting news in #Lupus! Our latest study is out. Discover how urinary biomarkers can transform lupus nephritis diagnosis & guide treatment. Plus novel insights into disease mechanism 🚀🚀. Dive into the research here https://t.co/mLVf94Fwye
#Rheumatology #Nephrology
Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis: https://t.co/ax77qPy0RL
@andreafava @HopkinsMedicine
#Nephrology
4
16
54
Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis: https://t.co/ax77qPy0RL
@andreafava @HopkinsMedicine
#Nephrology
1
2
6
Wonderful presentation by @celia_ida on a possibly novel cell type implicated in lupus nephritis #ACR23 #ACRBest
A#2427 #ACR23 @RheumNow PR3+ cell abundance higher in prolif LN, more than membranous. Mostly in tuberulointerstitium Density of PR3+ higher in glomueruli of prolif LN Correlates with activity, not chronicity Urinary PR3 predict renal fxn loss at 3y @jhrheumatology @andreafava
0
2
9
Honoured to receive this award! Huge thanks to @LupusAcademy for the opportunity and gratitude to my mentor @andreafava for guiding me every step of the journey! 🙏🏻#grateful #AwardWinning
Congratulations to the Poster Oral Presenters. The reviewers praised all of them, with the final prize going to Alessandra Ida Celia #lupus2023
1
1
14
CONGRESS #EULAR2023 | @andreafava presented data on urinary biomarker levels at 3 months predicting treatment response at 12 months. CD206, CD163 and IL16 better predict treatment response in proliferative LN than proteinuria. #Lupus #lupusnephritis
1
8
19
‼️ Application Opening ‼️ Join us as a postdoc #T32 research fellow in the Division of #Rheumatology! Learn more: https://t.co/i3NRCWSxCu
0
6
14
Kicking us off this morning: Many of our @HopkinsMedicine rheumatologists are presenting during the #ACR22 virtual and in-person poster sessions starting at 9am. Join @BritAdlerMD @andreafava @ZsuzsMcMahanMD @CaoilfhionnMD and others.
1
1
6
Find out about recent efforts to deliver more targeted & effective #rheum treatments during a session at #ACR22. Read a preview in ACR Convergence Today → https://t.co/yE7rApVB9p
@andreafava
1
11
20
#Hiring Join our research @HopkinsRheum to discover new treatments and molecularly redefine kidney #lupus using many omics? Computational only or hybrid with wet lab experience. Fun guaranteed. Physician-scientists most welcome. T32. DM me! @LupusOrg @RheumResearch
0
1
12
IL-16 is linked to lupus nephritis activity: a novel biomarker and potential therapeutic target discovered by the Accelerating Medicines Partnership! https://t.co/ir8iE3WNii
@soumya_boston @Deepakarao @HopkinsMedNews @jhrheumatology @RheumNow @NIH_NIAMS @LupusOrg @LupusResearch
acrjournals.onlinelibrary.wiley.com
Objective Current lupus nephritis (LN) treatments are effective in only 30% of patients, emphasizing the need for novel therapeutic strategies. We undertook this study to develop mechanistic hypoth...
3
17
48
Follow some of our Johns Hopkins rheumatologists on Twitter: @BritAdlerMD
@cappelliMD
@DrLisaCS
@JuliePaikMD
@MymaAlbaydaMD
@andreafava
@philseo
@MaxKonigMD
#ACR21 #RheumTwitter #rheumatology @HopkinsMedicine
0
2
21